Biotech Values

[JohnWayne]

CLVS - Thanks. I'd note that there were only 20 platinum-resistant pts in the CLVS dataset, so I wouldn't put too much stock in the comparison to Lynparza platinum-resistant data, especially since the efficacy looked so much better in platinum-sensitive pts anyway. IMO rucaparib still looks as good or slightly better than Lynparza, though the TSRO data are probably the more serious competitive threat.